@article{56d87c8fedfc43d4b349f5a79a298544,
title = "Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial",
abstract = "Ketamine is an N-methyl-D-aspartate receptor antagonist with rapid antidepressant effects. Studies suggest that inhibition of nitric oxide synthesis plays a role in the mechanism of action of ketamine. This randomized, placebo-controlled study investigated whether co-administration of sodium nitroprusside, a nitric oxide donor, compared to placebo, would attenuate the antidepressant and dissociative effects of ketamine. Sixteen ketamine responders were randomized to a double-blind infusion of ketamine co-administered with placebo or sodium nitroprusside. Our findings show no difference between the two conditions suggesting that the nitric oxide pathway may not play a primary role in ketamine{\textquoteright}s antidepressant or dissociative effects. The study is registered at clinicaltrials.gov (NCT03102736).",
keywords = "Depression, N-methyl-D-aspartate receptor, antidepressant, dissociation, glutamate, ketamine, nitric oxide, sodium nitroprusside",
author = "Laura Bevilacqua and Alex Charney and Pierce, {Charlotte R.} and Richards, {Samantha M.} and Jha, {Manish K.} and Andrew Glasgow and Jess Brallier and Katherine Kirkwood and Emilia Bagiella and Charney, {Dennis S.} and Murrough, {James W.}",
note = "Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by the Ehrenkranz Laboratory for Human Resilience, a component of the Depression and Anxiety Center for Discovery and Treatment at the ISMMS. The content is solely the responsibility of the authors and does not necessarily represent the views of the funding bodies. Funding Information: The authors would like to thank the research pharmacists at the Icahn School of Medicine at Mount Sinai (ISMMS), including Ivy Cohen, Alla Khodzhayeva, and Giuseppe Difiore and the Clinical Research Unit nursing staff at the ISMMS for their extensive work on this project. They also want to thank Dan Iosifescu, Charles Kellner, Emilia Bagiella, Mark Green, Lawrence Price, and Menachem Weiner for their assistance and study oversight as members of the Mount Sinai Ketamine Data and Safety Monitoring Board/Ketamine Oversight Committee. Finally, the authors wish to thank all of the patients who volunteered to participate in the study. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by the Ehrenkranz Laboratory for Human Resilience, a component of the Depression and Anxiety Center for Discovery and Treatment at the ISMMS. The content is solely the responsibility of the authors and does not necessarily represent the views of the funding bodies. Funding Information: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: In the past 5 years, JWM has provided consultation services and/or served on advisory boards for Allergan, Boehreinger Ingelheim, Clexio Biosciences, Fortress Biotech, FSV7, Global Medical Education (GME), Impel Neuropharma, Janssen Research and Development, Medavante-Prophase, Novartis, Otsuka, and Sage Therapeutics. In the past 12 months, JWM has provided consultation services and/or served on advisory boards for Boehreinger Ingelheim, Clexio Biosciences, Global Medical Education (GME), and Otsuka. JWM is named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders and on a patent pending for the use of ezogabine and other KCNQ channel openers to treat depression and related conditions. MKJ has received contract research grants from Acadia Pharmaceuticals and Janssen Research & Development, and honoraria for CME presentations from North American Center for Continuing Medical Education and Global Medical Education. DSC is named as co-inventor on patents filed by the ISMMS relating to the treatment for treatment-resistant depression, suicidal ideation and other disorders. ISMMS has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. and it has and will receive payments from Janssen under the license agreement related to these patents for the treatment of treatment resistant depression and suicidal ideation. Consistent with the ISMMS Faculty Handbook (the medical school policy), DSC is entitled to a portion of the payments received by the ISMMS. Since SPRAVATO has received regulatory approval for treatment-resistant depression, ISMMS and thus, through the ISMMS, DSC will be entitled to additional payments, beyond those already received, under the license agreement. DSC is a named co-inventor on several patents filed by ISMMS for a cognitive training intervention to treat depression and related psychiatric disorders. The ISMMS has entered into a licensing agreement with Click Therapeutics, Inc. and has and will receive payments related to the use of this cognitive training intervention for the treatment of psychiatric disorders. In accordance with the ISMMS Faculty Handbook, DSC has received a portion of these payments and is entitled to a portion of any additional payments that the medical school might receive from this license with Click Therapeutics. DSC is a named co-inventor on a patent application filed by the ISMMS for the use of intranasally administered Neuropeptide Y (NPY) for the treatment of mood and anxiety disorders. This intellectual property has not been licensed. DSC is a named coinventor on a patent application in the USA, and several issued patents outside the USA filed by the ISMMS related to the use of ketamine for the treatment of post-traumatic stress disorder (PTSD). This intellectual property has not been licensed. The other authors report no financial relationships with commercial interests. Publisher Copyright: {\textcopyright} The Author(s) 2021.",
year = "2021",
month = feb,
doi = "10.1177/0269881120985147",
language = "English (US)",
volume = "35",
pages = "124--127",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "2",
}